GEODE CAPITAL MANAGEMENT, LLC - BRAINSTORM CELL THERAPEUTICS ownership

BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 49 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q2 2022. The put-call ratio across all filers is 0.17 and the average weighting 0.0%.

Quarter-by-quarter ownership
GEODE CAPITAL MANAGEMENT, LLC ownership history of BRAINSTORM CELL THERAPEUTICS
ValueSharesWeighting
Q3 2023$62,218
-89.0%
310,777
+12.7%
0.00%
Q2 2023$567,954
-37.6%
275,7060.0%0.00%
Q1 2023$909,829
+202986.8%
275,706
+0.7%
0.00%
Q4 2022$448
-100.0%
273,706
-1.1%
0.00%
Q3 2022$1,222,000
+60.6%
276,636
+0.3%
0.00%
Q2 2022$761,000
-20.1%
275,909
-2.7%
0.00%
Q1 2022$952,000
-14.4%
283,485
+1.9%
0.00%
Q4 2021$1,112,000
+22.3%
278,101
+0.9%
0.00%
Q3 2021$909,000
-9.7%
275,750
+4.0%
0.00%
Q2 2021$1,007,000
-45.0%
265,138
-44.6%
0.00%
Q1 2021$1,831,000
-0.3%
478,258
+17.8%
0.00%
Q4 2020$1,836,000
-72.9%
405,923
+1.5%
0.00%
-100.0%
Q3 2020$6,766,000
+53.4%
399,906
+1.6%
0.00%0.0%
Q2 2020$4,411,000
+461.2%
393,522
+132.1%
0.00%
Q1 2020$786,000
-35.9%
169,585
-40.8%
0.00%
Q4 2019$1,226,000
+119.7%
286,472
+100.0%
0.00%
Q3 2019$558,000
+7.1%
143,236
+8.5%
0.00%
Q2 2019$521,000
+14.3%
132,063
+25.4%
0.00%
Q1 2019$456,000
-38.9%
105,273
-50.0%
0.00%
Q4 2018$746,000
+85.6%
210,546
+100.0%
0.00%
Q3 2018$402,000
-2.0%
105,2730.0%0.00%
Q2 2018$410,000
+52.4%
105,273
+22.8%
0.00%
Q1 2018$269,000
-19.7%
85,7100.0%0.00%
Q4 2017$335,000
-5.1%
85,7100.0%0.00%
Q3 2017$353,000
-0.8%
85,7100.0%0.00%
Q2 2017$356,000
+14.5%
85,710
+16.8%
0.00%
Q1 2017$311,000
+100.6%
73,366
+19.7%
0.00%
Q4 2016$155,000
+6.2%
61,2690.0%0.00%
Q3 2016$146,000
-0.7%
61,2690.0%0.00%
Q2 2016$147,000
-9.8%
61,2690.0%0.00%
Q1 2016$163,000
-6.9%
61,2690.0%0.00%
Q4 2015$175,000
+25.0%
61,2690.0%0.00%
Q3 2015$140,000
-36.7%
61,2690.0%0.00%
Q2 2015$221,000
-18.8%
61,2690.0%0.00%
Q1 2015$272,000
+231.7%
61,269
+255.5%
0.00%
Q4 2014$82,00017,2350.00%
Other shareholders
BRAINSTORM CELL THERAPEUTICS shareholders Q2 2022
NameSharesValueWeighting ↓
Weaver Consulting Group 130,000$437,0000.21%
Ikarian Capital, LLC 304,161$1,022,0000.13%
ABNER HERRMAN & BROCK LLC 265,000$890,0000.12%
S.C. Financial Services, Inc. 15,285$51,0000.06%
JMAC ENTERPRISES LLC 45,430$153,0000.04%
CFO4Life Group, LLC 12,000$40,0000.01%
OSAIC HOLDINGS, INC. 10,839$1,329,0000.00%
INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC 3,000$10,0000.00%
BOOTHBAY FUND MANAGEMENT, LLC 29,186$98,0000.00%
RAYMOND JAMES & ASSOCIATES 190,403$640,0000.00%
View complete list of BRAINSTORM CELL THERAPEUTICS shareholders